Literature DB >> 4038395

Canine hemangiosarcoma: retrospective analysis of 104 cases.

N O Brown, A K Patnaik, E G MacEwen.   

Abstract

Hemangiosarcoma was diagnosed in 104 dogs. The mean age was 10 years. Twenty-two breeds were represented. The most common were the German Shepherd Dog and Poodle. Most tumors were in the spleen (65/104). Other primary sites included the soft tissues of the trunk and extremities (18), liver (6), heart (3), and lung (2). Sixty of the dogs were examined because of rupture of the primary tumor or metastatic disease. Of the 104 dogs, 4 are alive and 100 are dead: 35 were euthanatized at the time of diagnosis, and the remaining 65 had a mean survival time of 123 days. The mean survival time of the 4 living dogs was 360 days. Forty-seven of the 65 dogs with splenic hemangiosarcoma were treated with surgery alone, surgery and immunotherapy, or surgery, immunotherapy, and combination chemotherapy. The same 47 dogs were clinically staged. There was no difference in survival time according to therapy or stage of disease.

Entities:  

Mesh:

Year:  1985        PMID: 4038395

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  41 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  Comparative evaluation of the liver in dogs with a splenic mass by using ultrasonography and contrast-enhanced computed tomography.

Authors:  Roelof A Irausquin; Thomas D Scavelli; Lisa Corti; Joseph D Stefanacci; Joann DeMarco; Shannon Flood; Barton W Rohrbach
Journal:  Can Vet J       Date:  2008-01       Impact factor: 1.008

3.  Primary peri-aortic hemangiosarcoma in a dog.

Authors:  Justin Guinan; Anthony Fischetti; Ana Paula Garate; Serge Chalhoub
Journal:  Can Vet J       Date:  2012-11       Impact factor: 1.008

4.  Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Hiroki Sakai; Satoshi Takagi
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

5.  Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).

Authors:  Karen Batschinski; Alessandra Nobre; Ernesto Vargas-Mendez; Marcello V Tedardi; Juliana Cirillo; Greice Cestari; Rodrigo Ubukata; Maria Lucia Z Dagli
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

6.  Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013).

Authors:  Steve G Patten; Sarah E Boston; Gabrielle J Monteith
Journal:  Can Vet J       Date:  2016-08       Impact factor: 1.008

7.  Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.

Authors:  A Carlson; K S Alderete; M K O Grant; D M Seelig; L C Sharkey; B N M Zordoky
Journal:  Vet Comp Oncol       Date:  2017-12-13       Impact factor: 2.613

Review 8.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

9.  Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.

Authors:  Nasim Akhtar; Marcia L Padilla; Erin B Dickerson; Howard Steinberg; Matthew Breen; Robert Auerbach; Stuart C Helfand
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

10.  Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed.

Authors:  Beth A Tamburini; Susan Trapp; Tzu Lip Phang; Jill T Schappa; Lawrence E Hunter; Jaime F Modiano
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.